Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA 02111, USA; Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, MA 02111, USA; Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111, USA; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA 02115, USA.
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA 02111, USA; Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Boston, MA 02111, USA; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA 02115, USA.
Cell Rep Med. 2022 Sep 20;3(9):100737. doi: 10.1016/j.xcrm.2022.100737. Epub 2022 Sep 8.
A challenge in tuberculosis treatment regimen design is the necessity to combine three or more antibiotics. We narrow the prohibitively large search space by breaking down high-order drug combinations into drug pair units. Using pairwise in vitro measurements, we train machine learning models to predict higher-order combination treatment outcomes in the relapsing BALB/c mouse model. Classifiers perform well and predict many of the >500 possible combinations among 12 antibiotics to be improved over bedaquiline + pretomanid + linezolid, a treatment-shortening regimen compared with the standard of care in mice. We reformulate classifiers as simple rulesets to reveal guiding principles of constructing combination therapies for both preclinical and clinical outcomes. One example ruleset combines a drug pair that is synergistic in a dormancy model with a pair that is potent in a cholesterol-rich growth environment. These rulesets are predictive, intuitive, and practical, thus enabling rational construction of drug combinations.
结核病治疗方案设计面临的一个挑战是需要将三种或更多种抗生素联合使用。我们将高序药物组合分解为药物对单元,从而缩小了搜索空间。通过使用体外的两两比较测量,我们使用机器学习模型来预测在复发性 BALB/c 小鼠模型中更高阶组合治疗结果。分类器表现良好,预测了 12 种抗生素中超过 500 种可能的组合,这些组合比在小鼠中与标准护理相比可缩短治疗时间的贝达喹啉+普托马尼德+利奈唑胺治疗方案更好。我们将分类器重新表述为简单的规则集,以揭示构建针对临床前和临床结果的组合疗法的指导原则。一个示例规则集将在休眠模型中具有协同作用的药物对与在富含胆固醇的生长环境中具有强大作用的药物对组合在一起。这些规则集具有可预测性、直观性和实用性,因此能够合理构建药物组合。